Yanay Ofran

Yanay Ofran transitioned from interim CEO to a Board Member in March of 2021. The founder of three biotech companies, Yanay has raised over $100 million from top venture capitalists and strategic investors. As a CEO and chairman of his companies, he has negotiated and signed dozens of joint ventures, technology deals and asset deals with pharmaceutical and biotechnology companies with upfront and potential milestone and royalty payments of over $1 billion. His scientific work focuses on the application of AI and computational biology to the study of genomes, diseases and drugs. Yanay founded Biolojic Design based on findings and approaches he developed to predict and design the interactions between antibodies and proteins. Combining computational approaches with protein engineering technologies, Biolojic’s platform has generated many novel promising drug leads with first- or best-in-class potential. Yanay is also the co-founder and chairman of Ukko, a VC-backed biotech company that designs healthy and safe proteins for the food and agricultural sectors. In 2020, Yanay co-founded Aulos Bioscience to revolutionize the treatment of cancer with a computationally designed antibody.

Yanay received his Ph.D. in molecular biophysics and biomedical informatics with distinction from Columbia University and was a professor of bioinformatics and molecular research at Bar Ilan University near Tel Aviv. He is the author of over 100 papers and patents.